

## **Alberta Drug Benefit List (ADBL) Interim Update now available online**

Please be advised that the **June 1, 2020** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at [www.ab.bluecross.ca/dbl/publications.php](http://www.ab.bluecross.ca/dbl/publications.php).

Please refer to the June 1, 2020 updates for complete listings of products available by special authorization, products with changes to criteria for coverage, restricted benefits, added products, new established interchangeable groupings, LCA price changes, products with a price change, and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at [www.ab.bluecross.ca/dbl/idbl\\_main1.php](http://www.ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

### **Temporary benefit added to the Alberta Drug Benefit List (ADBL)**

Due to the unavailability of Teva-Cephalexin 250 50 mg/ml Oral Suspension (DIN 00342092) and Teva-Cephalexin 125 25 mg/ml Oral Suspension (DIN 00342106), manufactured by Teva Canada Limited, Lupin-Cephalexin 50 mg/ml Oral Suspension (DIN 02469189), manufactured by Lupin Pharma Canada Limited, will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **May 20, 2020**, all claims for Lupin-Cephalexin 50 mg/ml Oral Suspension (DIN 02469189) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [www.ab.bluecross.ca/providers/pharmacy-home.php](http://www.ab.bluecross.ca/providers/pharmacy-home.php)

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

### **Temporary benefit added to the Alberta Human Services Drug Benefit Supplement (HSDBS)**

Due to the unavailability of The Magic Bullet 10 mg Rectal Suppository (DIN 02241091), manufactured by D&C Mobility Solutions Inc., Bisacodyl 10 mg Rectal Suppository (DIN 02361450), manufactured by Jamp Pharma Corporation, will be considered as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

As of **May 5, 2020**, all claims for Bisacodyl 10 mg Rectal Suppository (DIN 02361450) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [www.ab.bluecross.ca/providers/pharmacy-home.php](http://www.ab.bluecross.ca/providers/pharmacy-home.php)

If this situation continues to be a long-term matter then this product is subject to the usual review process and must be approved by the Minister of Health for addition to the *HSDBS* to remain as a benefit.

... continued from previous page

## Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Ranbaxy Pharmaceuticals Canada Inc that the shortage for Ran-Ramipril HCTZ 2.5 mg/12.5 mg Tablet (DIN 02449439) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 10, 2020**.

### RAMIPRIL / HYDROCHLOROTHIAZIDE

#### 2.5 MG / 12.5 MG TABLET

00002449439	RAN-RAMIPRIL HCTZ	RAN	\$ 0.1495
00002283131	ALTACE HCT	VCL	\$ 0.3138

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Carbamazepine 20 mg/ml Oral Suspension (DIN 02367394) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 22, 2020**.

### CARBAMAZEPINE

#### 20 MG / ML ORAL SUSPENSION

00002367394	TARO-CARBAMAZEPINE	TAR	\$ 0.0728
00002194333	TEGRETOL	NOV	\$ 0.0842

Alberta Blue Cross has been advised by Sanis Health Inc. and Sivem Pharmaceuticals ULC. that the shortage for Telmisartan 40 mg Tablet (DIN 02388944) and Telmisartan 40 mg Tablet (DIN 02390345) respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 22, 2020**.

### TELMISARTAN

#### 40 MG TABLET

00002453568	AURO-TELMISARTAN	AUR	\$ 0.2161
00002375958	SANDOZ TELMISARTAN	SDZ	\$ 0.2161
00002388944	TELMISARTAN	SNS	\$ 0.2161
00002390345	TELMISARTAN	SIV	\$ 0.2161
00002407485	TELMISARTAN	AHI	\$ 0.2161
00002320177	TEVA-TELMISARTAN	TEV	\$ 0.2161
00002240769	MICARDIS	BOE	\$ 1.2474

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

